A 9-year-old boy with past history of guttate psoriasis presented with a 1-month history of back pain, which progressively worsened and involved pain in the lower extremities. The patient underwent further evaluation that confirmed the diagnosis of L3 Ewing's sarcoma. He was treated according to the Children's Oncology Group protocol AEWS0031 and he successfully achieved CR post therapy. Two years later, the disease relapsed and salvage therapy was initiated using ifosfamide, carboplatin and etoposide. The patient had a very good partial response and therapy was consolidated with high-dose chemotherapy (HDCT) followed by autologous stem cell rescue (ASCR). During the pre-transplant period, the patient's psoriasis status remained stable without pharmacologic management. However, one week before admission for ASCR, the patient presented with generalized flare of his psoriasis covering approximately 100% of his body surface area. He had multiple discrete, erythematous, circular, macular lesions with uniform distribution involving primarily the scalp, torso, face and abdomen (Figure 1 ). Moreover, guttate lesions extended to the upper and lower extremities sparing palms and soles. At this time, dermatology was consulted, and confirmed the diagnosis of 'guttate psoriasis'.
The team continued with HDCT as planned and the patient received myeloablative conditioning with BU (0.8 mg/kg/dose intravenously every 6 h Â 16 doses on days À 6 through À 2) and melphalan (160 mg/m 2 /dose intravenously on day À 2) before ASCR. Within 48 h, the patient started to show clinical improvement in his skin lesions. The lesions became more flat, less scaly and gradually started to decrease in number. When the patient was discharged from the hospital by day 20 post ASCR, he had nearly a complete resolution of his skin lesions. Unfortunately, 13 months following ASCR, a chest mass was detected, which was confirmed to be Ewing's sarcoma. However, the patient continues to show resolution of his guttate lesions ( Figure 2 ) until the day of this report, approximately 15 months post ASCR.
Psoriasis is a chronic, inflammatory autoimmune disorder primarily affecting the skin and joints. Management strategies are based on the classification, area of involvement and severity of the condition as well as patient comorbidities. The continued development of various immunosuppressives and targeted biological agents has provided additional therapeutic options although with significant complications. 1 For this reason, alternative treatment strategies have been proposed including hematopoietic SCT (HSCT). A consensus statement published in 1997 from the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) recommended that autologous granulocyte colony-stimulating factor (G-CSF) peripheral stem cell-mobilized HSCT is relatively safe and should be considered for severe autoimmune disorders with increased risk of mortality, and before any irreversible organ damage takes place.
2 Seven years after the EULAR/EBMT position statement, almost 800 patients were documented within the European and North American databases, the majority were treated with autologous HSCT. 3 In a 10-year experience in a single institution, Gualandi et al. reported the outcomes of 32 patients that received autologous HSCT for a variety of severe autoimmune disorders. The majority received CY/G-CSF-mobilized peripheral CD34 þ stem cells. Two different preparative regimens were used, a myeloablative regimen that included BEAM (carmustine, etoposide, cytarabine, and melphalan) with or without antithymocyte globulin, or a reduced intensity regimen that included thiotepa and CY. The 10-year overall survival for all the patients was 97% and freedom from relapse of any kind was 66% at 8 years. 4 Information specifically related to HSCT in management of psoriatic disorders remains limited. A thorough literature review resulted in a few case reports, all in adult patients. In two case Figure 1 . Guttate lesions are depicted here on the patient's upper back and extremity on day À 6 before the administration of highdose chemotherapy. Lesions were also apparent on patient's scalp, torso, face and abdomen. reports, two patients received myeloablative conditioning and ASCR, and this resulted in long term resolution of severe and chronic psoriatic-arthritis conditions. 5, 6 One of the two patients continued to be in long-term remission 5 whereas the other had a mild clinical relapse 16 months following the transplant. 6 Three additional patients included within a review article achieved remission ranging 8-22 months. 3 A potential advantage following allogeneic HSCT is graft versus autoimmunity (GVI), which may eliminate self-reactive lymphocytes and host stem cells leading to the control of psoriatic arthritis. 3, [7] [8] [9] One case report discussed a patient with chronic myelogenous leukemia (CML) and severe psoriatic arthritis that showed a short-lived response of both diseases following non-myeloablative SCT, though both the diseases recurred shortly following the therapy. However, a longer and more permanent response of both the diseases for up to three years was successfully achieved by withdrawing graft versus host disease (GVHD) prophylaxis with CYA and the activation of alloreactive T-cells resulting in clinical GVHD. A similar possible GVI effect has also been previously reported by Snowden et al. In this report, three patients with rheumatoid arthritis and one with psoriatic arthritis received allogeneic SCT with subsequent GVHD that could have resulted in an added GVI effect. Unfortunately, the effect in the patient with psoriasis and CML was short-lived. Unlike the patient with psoriasis described earlier, this patient did not develop GVHD. 7 Limited pediatric experience exists in the literature although recent reviews have evaluated the use of HSCT upfront for severe or refractory autoimmune disease. [10] [11] [12] In the largest published review on HSCT for pediatric autoimmune diseases, Rabusin et al. 12 reported data from the EBMT database with about 120 patients that received both autologous and allogeneic transplants. The majority of patients had juvenile idiopathic arthritis and received autologous HSCT, whereas autoimmune hemolytic anemia was the largest group to receive allogeneic HSCT.
To our knowledge, this is the first report that describes the complete resolution of severe guttate psoriasis in a pediatric patient following ASCR for a malignant disorder. The patient's malignancy relapsed approximately 13 months post ASCR although he continues to be in CR from psoriasis 15 months following HDCT and ASCR. Late relapses of psoriasis have occurred up to 5 years following autologous HSCT and this patient continues to be closely followed by his primary oncologist. This report adds to the current literature suggesting the safe and effective use of HSCT in pediatric patients with underlying malignancies and concomitant autoimmune disease.
